Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

31/01/2015 Iranian entrepreneurs at the ALBA synchrotron 22/01/2015 What is a synchrotron and how it works? 15/01/2015 AFM2015 at ICMAB: Nanoscale Characterization of Functional Materials 08/01/2015 Ice under investigation: ICN2 and ICMAB sign an agreement with SnowWorld 23/12/2014 Kymos Pharma Services in the PTV 18/12/2014 Barcelona is one of the 20 best cities for students
35 36 37 38 39 40 41 42 43 44 45